Ulcerative colitis as a progressive disease: The forgotten evidence

Inflammatory Bowel Diseases

Volumn 18, Issue 7, 2012, Pages 1356-1363

  Torres, Joana ^a   Billioud, Vincent ^b   Sachar, David B ^a   Peyrin Biroulet, Laurent ^b   Colombel, Jean Fred́éric ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Bowel damage; Complications of IBD; Ulcerative colitis

Indexed keywords

ANORECTAL DISEASE; ANORECTAL PRESSURE; CHRONIC INFLAMMATION; COLON MOTILITY; COLON OBSTRUCTION; CROHN DISEASE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; FECES INCONTINENCE; GASTROINTESTINAL MOTILITY DISORDER; HUMAN; INCIDENCE; INTESTINAL FIBROSIS; INTESTINE INJURY; INTESTINE MUCOSA PERMEABILITY; INTESTINE POLYP; PRIORITY JOURNAL; PROCTITIS; PROGNOSIS; PSEUDOPOLYPOSIS; REVIEW; SIGMOIDOSCOPY; SYMPTOM; ULCERATIVE COLITIS;

COLITIS, ULCERATIVE; DISEASE PROGRESSION; HUMANS; PROGNOSIS;

EID: 84862196654     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.22839     Document Type: Review

References (73)

1. Sandborn WJ. Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology. 2008;135:1442-1447.
2. Sandborn WJ, Colombel JF, Lomax KG, et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: data from extend. Gut. 2011;60:A136-A137.
3. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology. 2010;138:463-468.
4. Pariente B, Cosnes J, Danese S, et al. Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis. 2011;17:1415-1422.
5. Ekbom A, Helmick CG, Zack M, et al. Survival and causes of death in patients with inflammatory bowel disease: a population-based study. Gastroenterology. 1992;103:954-960.
6. Winther KV, Jess T, Langholz E, et al. Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County. Gastroenterology. 2003;125:1576-1582. (Pubitemid 37500420)
7. Jess T, Loftus EV Jr, Harmsen WS, et al. Survival and cause specific mortality in patients with inflammatory bowel disease: a long term outcome study in Olmsted County, Minnesota, 1940-2004. Gut. 2006; 55:1248-1254. (Pubitemid 44277354)
8. Ritchie JK, Powell-Tuck J, Lennard-Jones JE. Clinical outcome of the first ten years of ulcerative colitis and proctitis. Lancet. 1978;1: 1140-1143. (Pubitemid 8356447)
9. Lennard-Jones JE. The clinical outcome of ulcerative colitis depends on how much of the colonic mucosa is involved. Scand J Gastroenterol Suppl. 1983;88:48-53.
10. Farmer RG, Easley KA, Rankin GB. Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients. Dig Dis Sci. 1993;38:1137-1146. (Pubitemid 23175139)
11. Langholz E, Munkholm P, Davidsen M, et al. Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol. 1996;31:260-266.
12. Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009;44:431-440.
13. Ayres RC, Gillen CD, Walmsley RS, et al. Progression of ulcerative proctosigmoiditis: incidence and factors influencing progression. Eur J Gastroenterol Hepatol. 1996;8:555-558. (Pubitemid 26229964)
14. Meucci G, Vecchi M, Astegiano M, et al. The natural history of ulcerative proctitis: a multicenter, retrospective study. Gruppo di Studio per le Malattie Infiammatorie Intestinali (GSMII). Am J Gastroenterol. 2000;95:469-473.
15. Chatzicostas C, Roussomoustakaki M, Potamianos S, et al. Factors associated with disease evolution in Greek patients with inflammatory bowel disease. BMC Gastroenterol. 2006;6:21.
16. Chow DK, Leong RW, Tsoi KK, et al. Long-term follow-up of ulcerative colitis in the Chinese population. Am J Gastroenterol. 2009;104: 647-654.
17. Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009;44: 431-440.
18. Edwards FC, Truelove SC. Course and prognosis of ulcerative colitis. Gut. 1964;5:1-15.
19. De Dombal FT, Watts JM, Watkinson G, et al. Local complications of ulcerative colitis: stricture, pseudopolyposis, and carcinoma of colon and rectum. Br Med J. 1966;1:1442-1447.
20. Gumaste V, Sachar DB, Greenstein AJ. Benign and malignant colorectal strictures in ulcerative colitis. Gut. 1992;33:938-941.
21. Goulston SJM, McGovern VJ. The nature of benign strictures in ulcerative colitis. N Engl J Med. 1969;281:290-295.
22. Yamagata M, Mikami T, Tsuruta T, et al. Submucosal fibrosis and basic- fibroblast growth factor-positive neutrophils correlate with colonic stenosis in cases of ulcerative colitis. Digestion. 2011;84:12-21.
23. Freeman AH, Berridge FR, Dick AP, et al. Pseudopolyposis in Crohn's disease. Br J Radiol. 1978;51:782-787. (Pubitemid 9019438)
24. Goldgraber MB. Pseudopolyps in ulcerative colitis. Dis Colon Rectum. 1965;8:355-363
25. Kelly JK, Gabos S. The pathogenesis of inflammatory polyps. Dis Colon Rectum. 1987;30:251-254. (Pubitemid 17052678)
26. Kelly JK, Langevin JM, Price LM, et al. Giant and symptomatic inflammatory polyps of the colon in idiopathic inflammatory bowel disease. Am J Surg Pathol. 1986;10:420-428. (Pubitemid 16066444)
27. Maggs JRL, Browning LC, Warren BF, et al. Obstructing giant postinflammatory polyposis in ulcerative colitis: case report and review of the literature. J Crohns Colitis. 2008;2:170-180. (Pubitemid 351672119)
28. Koga H, Iida M, Aoyagi K, et al. Generalized giant inflammatory polyposis in a patient with ulcerative colitis presenting with protein-losing enteropathy. Am J Gastroenterol. 1995;90:829-831.
29. Maldonado TS, Firoozi B, Stone D, et al. Colocolonic intussusception of a giant pseudopolyp in a patient with ulcerative colitis: a case report and review of the literature. Inflamm Bowel Dis. 2004;10: 41-44. (Pubitemid 38072445)
30. Esaki M, Matsumoto T, Fuyuno Y, et al. Giant inflammatory polyposis of the cecum with repeated intussusception in ulcerative colitis: report of a case. Am J Gastroenterol. 2009;104:2873-2874.
31. Bryan RL, Newman J, Alexander-Williams J. Giant inflammatory polyposis in ulcerative colitis presenting with protein losing enteropathy. J Clin Pathol. 1990;43:346-347. (Pubitemid 20111792)
32. Van Moerkercke W, Deboever G, Lambrecht G, et al. Severe bridging fibrosis of the colon in a man with inflammatory bowel disease. Endoscopy. 2007;39 Suppl 1:E294.
33. Snape WJ Jr. The role of a colonic motility disturbance in ulcerative colitis. Keio J Med. 1991;40:6-8.
34. Coulie B, Camilleri M, Bharucha AE, et al. Colonic motility in chronic ulcerative proctosigmoiditis and the effects of nicotine on colonic motility in patients and healthy subjects. Aliment Pharmacol Ther. 2001;15:653-663. (Pubitemid 32385870)
35. Bassotti G, de Roberto G, Chistolini F, et al. Twenty-four-hour manometric study of colonic propulsive activity in patients with diarrhea due to inflammatory (ulcerative colitis) and non-inflammatory (irritable bowel syndrome) conditions. Int J Colorectal Dis. 2004;19: 493-497. (Pubitemid 39193817)
36. Bassotti G, Villanacci V, Mazzocchi A, et al. Colonic propulsive and postprandial motor activity in patients with ulcerative colitis in remission. Eur J Gastroenterol Hepatol. 2006;18:507-510. (Pubitemid 43832749)
37. Snape WJ Jr, Matarazzo SA, Cohen S. Abnormal gastrocolonic response in patients with ulcerative colitis. Gut. 1980;21:392-396. (Pubitemid 10056254)
38. Kern F Jr, Almy TP, Abbot FK, et al. The motility of the distal colon in nonspecific ulcerative colitis. Gastroenterology. 1951;19: 492-503.
39. Spriggs EA, Code CF, Bargen JA, et al. Motility of the pelvic colon and rectum of normal persons and patients with ulcerative colitis. Gastroenterology. 1951;19:480-491.
40. Loening-Baucke V, Metcalf AM, Shirazi S. Rectosigmoid motility in patients with quiescent and active ulcerative colitis. Am J Gastroenterol. 1989;84:34-39. (Pubitemid 19042994)
41. Reddy SN, Bazzocchi G, Chan S, et al. Colonic motility and transit in health and ulcerative colitis. Gastroenterology. 1991;101:1289-1297.
42. Snape WJJr, Williams R, Hyman PE. Defect in colonic smooth muscle contraction in patients with ulcerative colitis. Am J Physiol. 1991; 261:G987-991.
43. Koch TR, Carney JA, Go VL, et al. Spontaneous contractions and some electrophysiologic properties of circular muscle from normal sigmoid colon and ulcerative colitis. Gastroenterology. 1988;95:77-84.
44. Geboes K, Collins S. Structural abnormalities of the nervous system in Crohn's disease and ulcerative colitis. Neurogastroenterol Motil. 1998;10:189-202. (Pubitemid 28286846)
45. Bernardini N, Segnani C, Ippolito C, et al. Immunohistochemical analysis of myenteric ganglia and interstitial cells of Cajal in ulcerative colitis. J Cell Mol Med. 2011 [Epub ahead of print].
46. Villanacci V, Bassotti G, Nascimbeni R, et al. Enteric nervous system abnormalities in inflammatory bowel diseases. Neurogastroenterol Motil. 2008;20:1009-1016.
47. Ohlsson B, Veress B, Lindgren S, et al. Enteric ganglioneuritis and abnormal interstitial cells of Cajal: features of inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:721-726. (Pubitemid 46909986)
48. Choi K, Chen J, Mitra S, et al. Impaired integrity of DNA after recovery from inflammation causes persistent dysfunction of colonic smooth muscle. Gastroenterology. 2011;141:1293-1301.
49. Sandborn WJ, Van Assche GA, Reinisch W, et al. Induction and maintenance of clinical remission by adalimumab in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2011;140: S123-S124.
50. Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut. 2011 [Epub ahead of print].
51. De Dombal FT, Geffen N, Darnborough A, et al. Radiological appearances of ulcerative colitis: an evaluation of their clinical significance. Gut. 1968;9:157-163.
52. Alp MH, Sage MR, Grant AK. The significance of widening of the presacral space at contrast radiography in inflammatory bowel disease. Aust N Z J Surg. 1978;48:175-177. (Pubitemid 8380106)
53. Gore R, Stoker J. Imaging of the colon and rectum: inflammatory and neoplastic diseases. In: Diseases of the abdomen and pelvis. Hodler J, Schulthess GK, Zollikofer CL, eds. Milan: Springer. 2006:74-83.
54. Chrispin AR, Fry IK. The presacral space shown by barium enema. Br J Radiol. 1963;36:319-322.
55. Denis P, Colin R, Galmiche JP, et al. Elastic properties of the rectal wall in normal adults and in the patients with ulcerative colitis. Gastroenterology. 1979;77:45-48. (Pubitemid 9212881)
56. Rao SS, Read NW, Davison PA, et al. Anorectal sensitivity and responses to rectal distention in patients with ulcerative colitis. Gastroenterology. 1987;93:1270-1275. (Pubitemid 17167268)
57. Loening-Baucke V, Metcalf AM, Shirazi S. Anorectal manometry in active and quiescent ulcerative colitis. Am J Gastroenterol. 1989;84: 892-897. (Pubitemid 19219763)
58. Suzuki H, Fujioka M. Rectal pressure and rectal compliance in ulcerative colitis. Jpn J Surg. 1982;12:79-81. (Pubitemid 12069318)
59. Nejdfors P, Wang Q, Ekelund M, et al. Increased colonic permeability in patients with ulcerative colitis: an in vitro study. Scand J Gastroenterol. 1998;33:749-753. (Pubitemid 28358060)
60. Casellas F, Aguade S, Soriano B, et al. Intestinal permeability to 99mTc-diethylenetriaminopentaacetic acid in inflammatory bowel disease. Am J Gastroenterol. 1986;81:767-770. (Pubitemid 16024857)
61. Almer S, Franzen L, Olaison G, et al. Increased absorption of polyethylene glycol 600 deposited in the colon in active ulcerative colitis. Gut. 1993;34:509-513. (Pubitemid 23093494)
62. Falchuk KR, Isselbacher KJ. Circulating antibodies to bovine albumin in ulcerative colitis and Crohn's disease. Characterization of the antibody response. Gastroenterology. 1976;70:5-8.
63. Stevens TR, Winrow VR, Blake DR, et al. Circulating antibodies to heat-shock protein 60 in Crohn's disease and ulcerative colitis. Clin Exp Immunol. 1992;90:271-274.
64. O'Morain CA, Abelow AC, Chervu LR, et al. Chromium 51-ethylene- diaminetetraacetate test: a useful test in the assessment of inflammatory bowel disease. J Lab Clin Med. 1986;108:430-435. (Pubitemid 17184419)
65. Arslan G, Atasever T, Cindoruk M, et al. (51)CrEDTA colonic permeability and therapy response in patients with ulcerative colitis. Nucl Med Commun. 2001;22:997-1001. (Pubitemid 32783451)
66. Den Hond E, Hiele M, Evenepoel P, et al. In vivo butyrate metabolism and colonic permeability in extensive ulcerative colitis. Gastroenterology. 1998;115:584-590. (Pubitemid 28397293)
67. Gerova VA, Stoynov SG, Katsarov DS, et al. Increased intestinal permeability in inflammatory bowel diseases assessed by iohexol test. World J Gastroenterol. 2011;17:2211-2215.
68. Oriishi T, Sata M, Toyonaga A, et al. Evaluation of intestinal permeability in patients with inflammatory bowel disease using lactulose and measuring antibodies to lipid A. Gut. 1995;36:891-896.
69. Welcker K, Martin A, Kolle P, et al. Increased intestinal permeability in patients with inflammatory bowel disease. Eur J Med Res. 2004;9:456-460.
70. Gibson PR, van de Pol E, Barratt PJ, et al. Ulcerative colitis-a disease characterised by the abnormal colonic epithelial cell? Gut. 1988; 29:516-521.
71. Salim SY, Soderholm JD. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis. 2011;17:362-381.
72. Ochsenkühn T, D'Haens G. Current misunderstandings in the management of ulcerative colitis. Gut. 2011;60:1294-1299.
73. Panaccione R, Ghosh S, Middleton S, et al. Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis: the UC Success Trial. Gastroenterology. 2011;140:S-134.